Compare PAR & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAR | STTK |
|---|---|---|
| Founded | 1968 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 640.6M | 538.3M |
| IPO Year | 1995 | 2020 |
| Metric | PAR | STTK |
|---|---|---|
| Price | $14.54 | $6.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $33.20 | $10.00 |
| AVG Volume (30 Days) | ★ 1.2M | 539.5K |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $455,547,000.00 | $1,000,000.00 |
| Revenue This Year | $9.82 | N/A |
| Revenue Next Year | $11.27 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 30.16 | N/A |
| 52 Week Low | $11.59 | $0.71 |
| 52 Week High | $72.15 | $8.33 |
| Indicator | PAR | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 50.99 | 43.42 |
| Support Level | $13.85 | $5.85 |
| Resistance Level | $15.10 | $6.81 |
| Average True Range (ATR) | 0.98 | 0.46 |
| MACD | 0.04 | -0.08 |
| Stochastic Oscillator | 49.88 | 27.07 |
PAR Technology Corp is a foodservice technology company providing omnichannel cloud-based software and hardware solutions to the restaurant industry in three restaurant categories - quick service, fast casual, and table service - and the retail industry, including convenience and fuel retailers (C-Stores). Its product and service offerings include point-of-sale, customer engagement and loyalty, digital ordering and delivery, operational intelligence, payment processing, hardware, and related technologies, solutions, and services. The company generates revenue from subscription service, Sale of Hardware products, and Professional Service.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.